Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of Lipocine stock opened at $3.28 on Friday. The stock has a 50 day moving average of $3.68 and a 200 day moving average of $4.52. The firm has a market capitalization of $17.55 million, a price-to-earnings ratio of -4.32 and a beta of 1.42. Lipocine has a fifty-two week low of $2.91 and a fifty-two week high of $11.79.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.